To our knowledge, this is the first report on an NMA used to assess the efficacy and safety of oral insulin sensitizers (metformin, thiazolidinediones, inositol, and berberine) as an adjunct therapy to improve irregular menses, hyperandrogenism, and glucolipid metabolism abnormalities in women with PCOS. Here, INS is linked to polycystic ovary syndrome.